AAD Finds One Third of American’s Fail Quiz on Skin Cancer
A survey from the American Academy of Dermatology found that younger generations lack skin cancer knowledge.
Deucravacitinib Safe, Effective for Psoriasis
Deucravacitinib meets primary end points for treating moderate to severe psoriasis.
FDA Sets PDUFA Date for Bimekizumab
The FDA has set a Prescription Drug User Fee Act (PDUFA) date for bimekizumab (UCB) for the treatment of psoriasis.